stock fell 3.1% in pre-open trading to reach $156.85, extending a corrective trend that took hold after three organizations flagged safety concerns tied to the company’s Prader-Willi syndrome treatment, Vykat XR.
The groups issued a joint statement pointing to post-marketing safety data showing seven patient deaths and more than 100 reports of serious adverse events since the drug’s approval in March 2025. They stopped short of asserting the drug caused the outcomes, noting the reports do not establish a causal relationship.
An FDA database lists four deaths associated with the medication.
Vykat XR treats hyperphagia, the chronic, insatiable hunger that characterizes Prader-Willi syndrome, a rare genetic disorder linked to missing or altered genetic material on chromosome 15 that disrupts normal gene regulation.
Neurocrine picked up the drug through its $2.9 billion acquisition of Soleno Therapeutics earlier this year.
A cluster of analyst upgrades in early August — including price-target increases from Wedbush, Canaccord, Citi, and a Buy reaffirmation from J.P. Morgan as recently as August 7 — helped the stock partially recover from the post-earnings lows, but no new analyst actions or corporate announcements have emerged today to provide fresh upside momentum.
Additionally, management’s acknowledgment that Medicare’s Inflation Reduction Act could create pricing pressure on INGREZZA between 2027 and 2029, without quantifying the potential impact, has left a key risk argument unresolved in investors’ minds.
https://ca.investing.com/news/stock-market-news/why-is-neurocrine-biosciences-stock-down-today-93CH-4794912
